| Name | Title | Contact Details |
|---|
ContraFect is a biotechnology company focused on discovering and developing therapeutic protein and antibody products for life-threatening, drug-resistant infectious diseases, particularly those treated in hospital settings. Due to drug-resistant and newly emerging pathogens, hospital acquired infections are currently the fourth leading cause of death in the United States, following heart disease, cancer and stroke. We intend to address drug-resistant infections using our therapeutic product candidates from our lysin and monoclonal antibody platforms to target conserved regions of either bacteria or viruses (regions that are not prone to mutation). ContraFect's initial product candidates include new agents to treat antibiotic-resistant infections such as MRSA (drug-resistant staphylococcus bacteria) and influenza.
Chart is a recognized global brand for the design and manufacture of highly engineered cryogenic equipment used from the beginning to the end in the liquid gas supply chain.
Synaptogenix is a clinical-stage biotech company leveraging Bryostatin-1 and its analogues to discover and develop targeted therapeutics for neurodegenerative diseases and developmental disorders.
Making advanced diagnostics and adoptive cell therapies more accessible by working from the bottom up via synthetic cells.
ShanghaiBio Corporation is a North Brunswick, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.